Welcome to the research library

Here our aim is to educate and build a community. Before buying peptides, it's important to know what they are and what they do.

Table of contents

  1. GHK-Cu
  2. Retatrutide
  3. Retatrutide and cancer research
  4. IGF1-LR3 and AOD-9604
  5. Additional notes on IGF1-LR3 and AOD-9604
  6. Mots-C

GHK-Cu: What Researchers Know

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a naturally occurring copper-binding peptide that has been studied for decades for its role in tissue repair, cellular signaling, and skin biology. First discovered in human plasma, GHK-Cu is found naturally throughout the body, although its levels are known to decline with age. Because of its broad biological activity, it has become one of the most widely researched peptides in regenerative science.

Researchers believe GHK-Cu functions primarily as a signaling molecule, helping regulate processes involved in collagen production, tissue remodeling, and cellular communication. Laboratory studies have examined its effects on fibroblasts, the cells responsible for producing collagen and elastin that help maintain healthy connective tissue. Other research has explored its potential role in wound healing, antioxidant activity, and hair follicle biology.

While many findings from cell and animal studies are promising, additional human research is needed to better understand the peptide's long-term biological effects and potential applications. GHK-Cu continues to be investigated across fields including dermatology, regenerative medicine, and healthy aging research.

At 51Peptides, we are committed to supplying high-quality research peptides backed by rigorous quality standards and third-party testing to support scientific investigation.

Disclaimer: GHK-Cu is offered for research use only. It is not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease and is not intended for human or veterinary use. Researchers are responsible for ensuring compliance with all applicable regulations and laboratory protocols.

Retatrutide: A Research Overview

Retatrutide is an investigational peptide that has generated significant interest in metabolic research due to its unique mechanism of action. Unlike many peptides that target a single receptor, Retatrutide is designed to activate three receptors involved in energy balance and metabolism: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-agonist approach has made it an important focus of ongoing scientific studies.

Researchers are investigating Retatrutide for its potential effects on appetite regulation, energy expenditure, glucose metabolism, and body weight. Early clinical research has shown promising results, leading to continued studies exploring its biological activity and long-term safety. Scientists believe the combined activation of these three pathways may produce effects that differ from peptides targeting GLP-1 alone.

Because Retatrutide remains an investigational compound, research is ongoing to better understand its pharmacology, optimal dosing strategies, and broader applications. Current studies continue to evaluate how it influences metabolic signaling and other physiological processes.

At 51Peptides, we provide high-quality research peptides supported by rigorous quality standards and third-party testing to help ensure identity and purity for laboratory research. Our goal is to support researchers with reliable materials for scientific investigation.

Disclaimer: Retatrutide is supplied for research use only. It is not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease and is not intended for human or veterinary use. Researchers are responsible for complying with all applicable laws, regulations, and institutional guidelines when handling research materials.

Retatrutide and cancer research

Emerging preclinical research has suggested that Retatrutide may influence cancer progression beyond its metabolic effects. In a 2025 study published in the NIH's PubMed Central, researchers evaluated Retatrutide in obese mouse models of pancreatic and lung cancer.

The results were notable:

  • Pancreatic cancer: Retatrutide produced a 14-fold reduction in tumor volume compared with untreated mice. In comparison, semaglutide produced approximately a 4-fold reduction under the same experimental conditions.
  • Tumor engraftment: Only 70% of mice treated with Retatrutide developed pancreatic tumors after cancer cell implantation, compared with 100% of untreated control mice.
  • Lung cancer: Retatrutide reduced tumor engraftment by approximately 50% and resulted in a 17-fold reduction in tumor volume compared with control animals.
  • Immune response: Researchers observed increased antigen-presenting immune cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways associated with anti-tumor immunity.

The investigators concluded that Retatrutide significantly delayed tumor onset and reduced tumor progression in these preclinical models. Interestingly, some anti-tumor effects persisted even after weight regain following discontinuation of the peptide, suggesting the observed benefits may not be explained solely by weight loss.

IGF-1 LR3 and AOD-9604: A Research Combination for Lean Mass and Fat Metabolism

IGF-1 LR3 and AOD-9604 are two research peptides that have attracted interest because they target different biological pathways. While IGF-1 LR3 has been investigated for its role in muscle cell growth and recovery, AOD-9604 has primarily been studied for its potential effects on fat metabolism. Together, they are often discussed as a research combination aimed at exploring body composition.

IGF-1 LR3 is a long-acting analog of insulin-like growth factor-1 (IGF-1). In laboratory research, IGF-1 signaling has been shown to promote protein synthesis, support muscle cell growth, and influence tissue repair. Because of its extended half-life compared to native IGF-1, IGF-1 LR3 has become a common tool in preclinical studies examining muscle development and anabolic signaling.

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that was designed to investigate fat metabolism without producing the growth-promoting effects associated with full-length growth hormone. Preclinical studies have suggested it may stimulate lipolysis and reduce lipogenesis, although larger human clinical trials did not demonstrate clinically meaningful weight-loss benefits compared with placebo.

From a research perspective, combining these compounds offers an opportunity to study two separate physiological processes simultaneously: IGF-1 LR3's influence on lean tissue and AOD-9604's effects on fat metabolism. However, there are currently no published clinical studies evaluating the combination of IGF-1 LR3 and AOD-9604 together, so any proposed synergistic effects remain theoretical rather than evidence-based.

Research Disclaimer: IGF-1 LR3 and AOD-9604 are intended for laboratory research only. They are not approved by the U.S. FDA for the diagnosis, treatment, cure, or prevention of any disease, and the information above is provided solely for educational and research purposes.

Additional Research Notes

Researchers are interested in the IGF-1 LR3 and AOD-9604 combination because the two peptides act through different biological mechanisms. Rather than targeting the same pathway, they have been investigated independently for separate areas of physiology, making them an interesting pairing for laboratory studies focused on body composition.

Some researchers theorize that IGF-1 LR3 may support an anabolic environment by promoting cellular growth and protein synthesis, while AOD-9604 has been studied for its potential influence on fat metabolism. This has led to interest in exploring whether the combination could produce complementary effects in preclinical models. However, these proposed benefits remain hypothetical, as the combination has not been adequately evaluated in controlled human clinical trials.

It is also important to recognize that responses to these compounds can vary depending on experimental conditions, dosage, duration of exposure, and the biological model being studied. Findings from cell culture or animal research should not be assumed to translate directly to humans.

As research continues, scientists hope to better understand how these peptides interact with metabolic and anabolic signaling pathways, as well as whether combining them offers any measurable advantages over studying each compound individually.

MOTS-c: A Mitochondrial-Derived Peptide in Metabolic Research

MOTS-c is a mitochondrial-derived peptide that has gained significant attention in metabolic and aging research. Unlike many peptides encoded by nuclear DNA, MOTS-c is produced from mitochondrial DNA, making it a unique signaling molecule involved in cellular energy regulation.

Preclinical research suggests that MOTS-c may help cells adapt to metabolic stress by influencing glucose metabolism, insulin sensitivity, and mitochondrial function. Laboratory studies have also shown that MOTS-c can activate pathways associated with energy homeostasis, including AMP-activated protein kinase (AMPK), often referred to as the body's "metabolic master switch."

Researchers have investigated MOTS-c for its potential role in improving metabolic flexibility, enhancing physical performance, and supporting healthy aging. Animal studies have demonstrated improvements in insulin sensitivity, increased glucose utilization, and enhanced exercise capacity under certain experimental conditions. These findings have made MOTS-c a growing area of interest for scientists studying obesity, type 2 diabetes, and age-related metabolic decline.

Despite these promising results, human research remains limited. While early clinical investigations have provided valuable insights into the peptide's biology, additional large-scale studies are needed to determine its safety, efficacy, and potential therapeutic applications.

As interest in mitochondrial health continues to grow, MOTS-c remains an important research tool for understanding how mitochondria communicate with the rest of the body and regulate metabolism at the cellular level.

Research Disclaimer: MOTS-c is intended for laboratory research only. It is not approved by the U.S. FDA for the diagnosis, treatment, cure, or prevention of any disease. The information provided is for educational and scientific purposes only.